JOP20220180A1 - مُعدلات ليباز أُحادِيُّ الجلِيسِريد - Google Patents
مُعدلات ليباز أُحادِيُّ الجلِيسِريدInfo
- Publication number
- JOP20220180A1 JOP20220180A1 JOP/2022/0180A JOP20220180A JOP20220180A1 JO P20220180 A1 JOP20220180 A1 JO P20220180A1 JO P20220180 A JOP20220180 A JO P20220180A JO P20220180 A1 JOP20220180 A1 JO P20220180A1
- Authority
- JO
- Jordan
- Prior art keywords
- methods
- disorders
- monoacylglycerol lipase
- modulators
- depression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
مركبات آزا ثنائي الحلقات 3.1.0 و4.1.0 بالصيغة (I) وتركيبات صيدلانية تحتوي عليها وطرق صنعها، وأساليب استخدامها بما في ذلك وسائل علاج الحالات المرضية والاضطرابات والظروف المرتبطة بتعديل ليباز أحادي الجلِيسِريد (MGL)، مثل تلك المرتبطة بالألم، الاضطرابات النفسية، الاضطرابات العصبية (بما في ذلك، على سبيل المثال لا الحصر، الاضطراب الاكتئابي الرئيسي، والاكتئاب المقاوم للعلاج، والاكتئاب الناتج عن القلق، والاضطراب ثنائي القطب)، والسرطانات وأمراض العيون. ؛ حيث يتم تعريف X، وY، وR1، وR2a، وR2b بهذا الاختراع.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062972484P | 2020-02-10 | 2020-02-10 | |
PCT/EP2021/053062 WO2021160602A1 (en) | 2020-02-10 | 2021-02-09 | Monoacylglycerol lipase modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20220180A1 true JOP20220180A1 (ar) | 2023-01-30 |
Family
ID=74595268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2022/0180A JOP20220180A1 (ar) | 2020-02-10 | 2021-02-09 | مُعدلات ليباز أُحادِيُّ الجلِيسِريد |
Country Status (21)
Country | Link |
---|---|
US (2) | US11708359B2 (ar) |
EP (1) | EP4103557A1 (ar) |
JP (1) | JP2023512729A (ar) |
KR (1) | KR20220140581A (ar) |
CN (1) | CN115066422A (ar) |
AR (1) | AR121296A1 (ar) |
AU (1) | AU2021220539A1 (ar) |
BR (1) | BR112022015116A2 (ar) |
CA (1) | CA3169988A1 (ar) |
CL (1) | CL2022002136A1 (ar) |
CO (1) | CO2022011275A2 (ar) |
CR (1) | CR20220376A (ar) |
DO (1) | DOP2022000162A (ar) |
EC (1) | ECSP22062460A (ar) |
IL (1) | IL295447A (ar) |
JO (1) | JOP20220180A1 (ar) |
MX (1) | MX2022009804A (ar) |
PE (1) | PE20221576A1 (ar) |
TW (1) | TW202140465A (ar) |
UY (1) | UY39066A (ar) |
WO (1) | WO2021160602A1 (ar) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3169988A1 (en) | 2020-02-10 | 2021-08-19 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
KR20220158060A (ko) | 2020-03-26 | 2022-11-29 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제로서의 아릴 피페리딘 |
WO2021191390A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Azaspirocycles as monoacylglycerol lipase modulators |
BR112022019178A2 (pt) | 2020-03-26 | 2022-11-01 | Janssen Pharmaceutica Nv | Aminociclobutanos como moduladores da monoacilglicerol lipase |
CN118076351A (zh) | 2021-08-09 | 2024-05-24 | 詹森药业有限公司 | 用于自闭症谱系障碍的单酰基甘油脂肪酶调节剂 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005537290A (ja) | 2002-07-25 | 2005-12-08 | ファルマシア・イタリア・エス・ピー・エー | キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物 |
EP2090576A1 (en) | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
MX2014003879A (es) * | 2011-09-30 | 2014-09-01 | Janssen Pharmaceutica Nv | Inhibidores de monoacilglicerol lipasa para el tratamiento de enfermedades metabolicas y trastornos relacionados. |
WO2017170830A1 (ja) | 2016-03-31 | 2017-10-05 | 武田薬品工業株式会社 | 複素環化合物 |
TWI738753B (zh) | 2016-03-31 | 2021-09-11 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
CN111148746B (zh) | 2017-09-29 | 2022-08-05 | 武田药品工业株式会社 | 杂环化合物 |
WO2020211798A1 (zh) | 2019-04-16 | 2020-10-22 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
CA3169988A1 (en) | 2020-02-10 | 2021-08-19 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
KR20220158060A (ko) | 2020-03-26 | 2022-11-29 | 얀센 파마슈티카 엔.브이. | 모노아실글리세롤 리파아제 조절제로서의 아릴 피페리딘 |
WO2021191390A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Azaspirocycles as monoacylglycerol lipase modulators |
BR112022019178A2 (pt) | 2020-03-26 | 2022-11-01 | Janssen Pharmaceutica Nv | Aminociclobutanos como moduladores da monoacilglicerol lipase |
-
2021
- 2021-02-09 CA CA3169988A patent/CA3169988A1/en active Pending
- 2021-02-09 CR CR20220376A patent/CR20220376A/es unknown
- 2021-02-09 BR BR112022015116A patent/BR112022015116A2/pt unknown
- 2021-02-09 US US17/171,559 patent/US11708359B2/en active Active
- 2021-02-09 WO PCT/EP2021/053062 patent/WO2021160602A1/en active Application Filing
- 2021-02-09 UY UY0001039066A patent/UY39066A/es unknown
- 2021-02-09 PE PE2022001698A patent/PE20221576A1/es unknown
- 2021-02-09 MX MX2022009804A patent/MX2022009804A/es unknown
- 2021-02-09 JO JOP/2022/0180A patent/JOP20220180A1/ar unknown
- 2021-02-09 IL IL295447A patent/IL295447A/en unknown
- 2021-02-09 AU AU2021220539A patent/AU2021220539A1/en active Pending
- 2021-02-09 JP JP2022548400A patent/JP2023512729A/ja active Pending
- 2021-02-09 KR KR1020227031216A patent/KR20220140581A/ko unknown
- 2021-02-09 TW TW110104960A patent/TW202140465A/zh unknown
- 2021-02-09 CN CN202180013762.3A patent/CN115066422A/zh active Pending
- 2021-02-09 EP EP21705124.2A patent/EP4103557A1/en active Pending
- 2021-02-09 AR ARP210100333A patent/AR121296A1/es unknown
-
2022
- 2022-08-08 CL CL2022002136A patent/CL2022002136A1/es unknown
- 2022-08-09 EC ECSENADI202262460A patent/ECSP22062460A/es unknown
- 2022-08-10 CO CONC2022/0011275A patent/CO2022011275A2/es unknown
- 2022-08-10 DO DO2022000162A patent/DOP2022000162A/es unknown
-
2023
- 2023-06-02 US US18/328,242 patent/US20230382902A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AR121296A1 (es) | 2022-05-04 |
IL295447A (en) | 2022-10-01 |
CA3169988A1 (en) | 2021-08-19 |
ECSP22062460A (es) | 2022-11-30 |
US11708359B2 (en) | 2023-07-25 |
CL2022002136A1 (es) | 2023-02-03 |
KR20220140581A (ko) | 2022-10-18 |
CO2022011275A2 (es) | 2022-08-30 |
MX2022009804A (es) | 2022-09-02 |
CR20220376A (es) | 2022-09-16 |
AU2021220539A1 (en) | 2022-10-06 |
PE20221576A1 (es) | 2022-10-06 |
EP4103557A1 (en) | 2022-12-21 |
UY39066A (es) | 2021-08-31 |
US20230382902A1 (en) | 2023-11-30 |
DOP2022000162A (es) | 2022-10-31 |
WO2021160602A1 (en) | 2021-08-19 |
TW202140465A (zh) | 2021-11-01 |
BR112022015116A2 (pt) | 2022-09-27 |
US20210253565A1 (en) | 2021-08-19 |
CN115066422A (zh) | 2022-09-16 |
JP2023512729A (ja) | 2023-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20220180A1 (ar) | مُعدلات ليباز أُحادِيُّ الجلِيسِريد | |
PH12021550659A1 (en) | Monoacylglycerol lipase modulators | |
MX2021003661A (es) | Moduladores de la monoacilglicerol lipasa. | |
MX2022011904A (es) | Aminociclobutanos como moduladores de monoacilglicerol lipasa. | |
MX2022011903A (es) | Azaspirociclos como moduladores de monoacilglicerol lipasa. | |
MX2022011901A (es) | Arilo piperidinas como moduladores de monoacilglicerol lipasa. | |
MX2022011902A (es) | Moduladores de la monoacilglicerol lipasa. | |
Harper et al. | Transplantation of BDNF-secreting mesenchymal stem cells provides neuroprotection in chronically hypertensive rat eyes | |
EA201100461A1 (ru) | Спиро-трициклические соединения как модуляторы бета-секретазы и способы их использования | |
KR101210984B1 (ko) | 음파를 이용한 중간엽 줄기세포의 신경세포 분화유도 방법 | |
MX366855B (es) | Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso. | |
MX2010010151A (es) | Moduladores de cinasa aurora y metodo de uso. | |
MX2022015613A (es) | Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental. | |
MX2012010657A (es) | Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico. | |
ATE289800T1 (de) | Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems | |
PE20231384A1 (es) | Agonistas de bicicloheptano pirrolidina de los receptores de orexina | |
MX2019007102A (es) | Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso. | |
MX2023003240A (es) | Moduladores de monoacilglicerol lipasa de ciclobutilamida. | |
EA201992127A1 (ru) | ФАРМАКОЛОГИЧЕСКИ АКТИВНЫЕ АЛИЦИКЛИЧЕСКИ ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА | |
MX2023003165A (es) | Moduladores de la caseína cinasa 1 delta. | |
Zuzic | Forward programming of photoreceptors from induced pluripotent stem cells | |
WO2024077043A3 (en) | Modifying early-stage parkinson's disease progression with deep brain stimulation | |
MX2023003170A (es) | Moduladores de la caseina cinasa 1 delta. | |
KR20130061970A (ko) | 복합파동을 이용한 줄기세포 분화 방법 및 장치 | |
EA202192737A1 (ru) | Генная терапия лизосомальных нарушений |